- Home
- BCSF vs JANX Comparison
BCSF vs JANX Comparison
Compare BCSF & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCSF | JANX |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 838.7M | 975.7M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BCSF | JANX |
|---|---|---|
| Price | $11.09 | $16.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 18 |
| Target Price | $12.63 | ★ $36.24 |
| AVG Volume (30 Days) | 474.3K | ★ 775.3K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | ★ 17.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | $194.24 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $41.76 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.95 | $12.12 |
| 52 Week High | $14.70 | $35.34 |
Technical Indicators
Market Signals| Indicator | BCSF | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 35.19 | 49.43 |
| Support Level | N/A | $15.75 |
| Resistance Level | $13.74 | $19.14 |
| Average True Range (ATR) | 0.20 | 0.65 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 16.28 | 76.38 |
Price Performance
Historical ComparisonAbout BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing in middle-market companies. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan, and others.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.